Cwm LLC Sells 860 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Cwm LLC lessened its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 13.8% during the 4th quarter, HoldingsChannel reports. The firm owned 5,379 shares of the company’s stock after selling 860 shares during the quarter. Cwm LLC’s holdings in Takeda Pharmaceutical were worth $77,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. FMR LLC boosted its holdings in shares of Takeda Pharmaceutical by 4.7% during the 3rd quarter. FMR LLC now owns 2,593,350 shares of the company’s stock worth $40,119,000 after buying an additional 115,947 shares during the period. Brandes Investment Partners LP lifted its position in Takeda Pharmaceutical by 2.1% during the 3rd quarter. Brandes Investment Partners LP now owns 1,802,036 shares of the company’s stock worth $27,877,000 after acquiring an additional 36,717 shares during the last quarter. Managed Asset Portfolios LLC boosted its holdings in Takeda Pharmaceutical by 1.5% during the third quarter. Managed Asset Portfolios LLC now owns 1,736,416 shares of the company’s stock valued at $26,862,000 after acquiring an additional 25,291 shares during the period. Envestnet Asset Management Inc. grew its position in shares of Takeda Pharmaceutical by 5.7% in the third quarter. Envestnet Asset Management Inc. now owns 1,512,936 shares of the company’s stock valued at $23,405,000 after purchasing an additional 81,267 shares during the last quarter. Finally, Van ECK Associates Corp increased its stake in shares of Takeda Pharmaceutical by 21.6% in the third quarter. Van ECK Associates Corp now owns 1,278,300 shares of the company’s stock worth $19,775,000 after purchasing an additional 226,754 shares during the period. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK opened at $13.28 on Wednesday. The business has a 50 day moving average price of $13.85 and a 200 day moving average price of $14.10. The company has a market cap of $42.03 billion, a price-to-earnings ratio of 20.12, a PEG ratio of 3.05 and a beta of 0.56. The company has a quick ratio of 0.55, a current ratio of 1.06 and a debt-to-equity ratio of 0.64. Takeda Pharmaceutical Company Limited has a twelve month low of $13.01 and a twelve month high of $17.11.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.